Shots:

• The companies entered into an agreement to register and commercialize denosumab (biosimilar referencing Prolia) for use in the EU- the UK- Switzerland- and Australia
• Enzene will exclusively supply the finished product to Theramex for the duration of the agreement
• Denosumab (SC- once every 6mos.) is a human mAb (IgG2) that targets and binds with high affinity and specificity to RANKL- preventing activation of its receptor- RANK- on the surface of osteoclast precursors and osteoclasts

  | Ref: Theramex | Image: Theramex